Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
13.5.2021 13:00:00 EEST | Business Wire | Press release
Knopp Biosciences LLC today announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference.
“We look forward to sharing comprehensive results of the EXHALE trial, which underscore the readiness of dexpramipexole for further development in eosinophilic asthma,” said Michael Bozik, M.D., president and CEO of Knopp. “Monoclonal antibody treatments approved for asthma demonstrate that reduction in eosinophils is associated with significantly improved outcomes, but the need remains for an oral alternative in the eosinophilic asthma treatment paradigm.”
Following are details of the poster presentation:
|
Poster Title |
Abstract Number / Presentation Details |
|
|
Oral Dexpramipexole Efficacy in Lowering Blood Eosinophils in Patients with Moderate to Severe Uncontrolled Eosinophilic Asthma
|
A1359 Poster Presentation
Presenter: Calman Prussin, M.D., VP, Clinical and Translational Medicine, Knopp Biosciences LLC
Time: 8 a.m. EDT
|
Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with conference news and updates using the hashtag #ATS2021.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and tinnitus. Please visit www.knoppbio.com.
ABOUT DEXPRAMIPEXOLE
Dexpramipexole, a selective inhibitor of eosinophil maturation, is an oral small molecule drug in development by Knopp for asthma and other eosinophil-associated diseases. In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission. In its earlier development in amyotrophic lateral sclerosis, dexpramipexole was shown to be well tolerated in Phase 1, Phase 2, and Phase 3 trials comprising approximately 1,200 patients.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events, or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.
Media inquiries:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005183/en/
Contact information
Tom Petzinger
tom@knoppbio.com
412-488-1776
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Investment Is Outpacing Organizations' Ability to Realize Value, New HTEC Research Finds15.9.2026 15:47:00 EEST | Press release
HTEC, a global product engineering and AI transformation company, today released preview findings from its AI Value Realization Report 2026, based on a survey of 1,500 C-level executives across the US, UK, Germany, and the UAE. The research reveals that AI investment is accelerating faster than organizations' ability to absorb it — creating a growing bottleneck between what companies are spending on AI and the value they are actually able to realize from it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915718678/en/ HTEC, a global product engineering and AI transformation company, today released preview findings from its AI Value Realization Report 2026, based on a survey of 1,500 C-level executives across the US, UK, Germany, and the UAE. Seventy-nine percent of executives report increased AI investment over the past ten months, with spending up by an average of 31%. But according to HTEC's findings, that capital is be
Telness Tech Becomes Valdyr, Making Seamless OS the AI-Native Execution Layer for Telecom Operators15.9.2026 15:30:00 EEST | Press release
Valdyr positions Seamless OS as the AI-native execution layer for telecom operators: the layer on which commercial decisions are carried out, rather than a system of record that reports on them. Offers, subscriptions, billing, provisioning, customer journeys and integrations run in one place, telecom processes are built as automated workflows instead of custom development, and AI is applied to commercial and customer-facing operations inside the platform rather than sold as a separate product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915818094/en/ Telness Tech is rebranding and becoming Valdyr The platform supports operators across the United States, Europe and beyond. Recent additions include Telia, the Nordic incumbent operator, and Truecaller, the caller-identification company. "We ran an operator on the same legacy systems everyone else runs on, and developed our way out of them, creating Seamless OS," said Mart
BMC TV expands UK network for major sports broadcasts with Adtran and Fibre Technologies Ltd15.9.2026 15:00:00 EEST | Press release
Adtran today announced that BMC TV has expanded its UK core network, harnessing Adtran technology to support coverage of major events, including the FIFA World Cup and extensive racecourse broadcasting across the UK. The new infrastructure strengthens BMC TV’s packet edge, access and aggregation layers, enabling reliable distribution of live feeds across multiple locations with deterministic, low-latency performance. Designed to scale with growing broadcast demands, the network also provides a clear route to future 400Gbit/s services. The deployment was delivered in partnership with Fibre Technologies Ltd, which led solution design, commercial engagement and implementation support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915498940/en/ Adtran’s technology is helping BMC TV expand its core network to deliver live sporting events across the UK. “Live sports coverage places intense and constantly changing demands on ou
Two Powerhouses, One Drive: SharkNinja Joins McLaren Racing as Official Partner15.9.2026 15:00:00 EEST | Press release
SharkNinja, Inc. (NYSE: SN), a global product design and technology company, is proud to announce its new global partnership with McLaren Racing, the renowned British motorsport team, across its Formula 1, IndyCar, World Endurance Championship, and F1 Academy entries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915026788/en/ As an Official Partner, SharkNinja will become part of the McLaren Racing ecosystem through exclusive experiences, content, and activations designed to connect fans with the ethos and innovation of the two brands. Through the McLaren Racing Accelerator Program, engineers from both companies will work together to apply advanced racing methodologies to the development of future SharkNinja products. “McLaren is one of the most decorated teams in motorsport history, built on a legacy of innovation, technical excellence, and performance at the highest level," said Mark Barrocas, Chief Executive Officer
The LYCRA Company Appoints Hua Du as Chief Executive Officer15.9.2026 15:00:00 EEST | Press release
The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, announced today that Hua Du has been appointed chief executive officer, effective September 14, as the company enters its next chapter following the successful completion of its financial restructuring. Du succeeds Dean Williams, who served as interim chief executive officer and will continue in his role as chief financial officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915565505/en/ The LYCRA Company Appoints Hua Du as Chief Executive Officer. With 30 years of leadership experience in the specialty chemical and biotechnology industries, Du is well positioned to lead the company into its next chapter. Du brings 30 years of leadership experience in the specialty chemical and biotech-based industries, driving transformational growth across global businesses. Du most recently served as CEO of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom